XML 27 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

(13) Segment Information

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM) or decision-making group, in making decisions on how to allocate resources and assess performance. The principal executive officer (PEO) is the CODM. The Company operates in one operating segment; discovery and development of Synthetic Biotics.

The CODM manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with long-term company-wide strategic goals. In making these decisions, the PEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the Company's consolidated net income (loss) that is reported on the consolidated statements of operations and comprehensive income (loss). Through this analysis, the CODM assesses performance by comparing actual consolidated net income (loss) versus the budget, and then decides how to allocate resources to invest in the Company's research and development programs. The measure of segment assets is reported on the consolidated balance sheets as total assets. In addition, research and development, general and administrative expenses, and restructuring charges are significant segment expenses regularly provided to the PEO with the following categories (in thousands):

Research and Development

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Clinical research and external costs

$

8

 

 

$

(852

)

 

$

23

 

 

$

4,062

 

Facility and all other costs

 

—

 

 

 

114

 

 

 

—

 

 

 

3,136

 

Compensation and benefits

 

—

 

 

 

25

 

 

 

(7

)

 

 

1,966

 

Total research and development expense

$

8

 

 

$

(713

)

 

$

16

 

 

$

9,164

 

General and Administrative

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Consulting and professional services

$

625

 

 

$

788

 

 

$

1,851

 

 

$

2,838

 

Compensation and benefits

 

139

 

 

 

342

 

 

 

433

 

 

 

1,603

 

Facility and all other costs

 

54

 

 

 

35

 

 

 

170

 

 

 

787

 

Total general and administrative expense

$

818

 

 

$

1,165

 

 

$

2,454

 

 

$

5,228

 

Restructuring Charges

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Facility and all other costs

$

—

 

 

$

35

 

 

$

(80

)

 

$

15,537

 

Compensation and benefits

 

58

 

 

 

221

 

 

 

167

 

 

 

8,245

 

Consulting and professional services

 

107

 

 

 

20

 

 

 

126

 

 

 

686

 

Clinical research and external costs

 

—

 

 

 

20

 

 

 

(17

)

 

 

322

 

Total restructuring charges

$

165

 

 

$

296

 

 

$

196

 

 

$

24,790